companies / profluent-bio
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-07 json
| total_raised | 44,000,00044.0M | ○ |
|---|---|---|
| founded | 2022 | |
| hq | Berkeley, US | |
| industry | unknown | |
| stage | series-a |
Profluent uses AI to design novel proteins for therapeutic and industrial use, including OpenCRISPR, an AI-designed gene editor it released openly. It works with pharma and biotech in genetic medicine and agriculture, partnering with Eli Lilly. Its models build on natural protein scaffolds or author entirely new ones.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-03-25 | series-a | 35,000,00035.0M | null | ○ |
Cloudflare, LottieFiles 5.13.0, Google Analytics, Google Font API, Google Hosted Libraries, Google Tag Manager, DoubleClick Floodlight, WordPress, PHP, MySQL, jquery 3.5.1
| fact | status | src |
|---|---|---|
| Series A, $35.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |